Barclays
RYTM icon

Barclays’s Rhythm Pharmaceuticals RYTM Stock Holding History

Barclays’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,600
Closed -$230K – 5447
2024
Q2 		$230K Hold
5,600
– – ﹤0.01% 3506
2024
Q1 		$243K Hold
5,600
– – ﹤0.01% 4009
2023
Q4 		$257K Buy
+5,600
New +$177K ﹤0.01% 4307

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Barclays's RYTM Position: Q1 2026 in Review

Barclays reduced its Rhythm Pharmaceuticals (RYTM) stake by 92% in Q1 2026, selling an estimated $11.7M and leaving 10,652 shares worth $926K. The position accounts for ﹤0.01% of the portfolio, ranked #2805.

Barclays first reported a position in RYTM in Q4 2017 and has held it in 34 quarters since. The position peaked at $22.2M in Q2 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Barclays held 10,652 shares of Rhythm Pharmaceuticals worth $926K as of Q1 2026.
  • Barclays sold 120,784 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $11.7M.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2805 holding.
  • Barclays first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
  • Barclays's Rhythm Pharmaceuticals position peaked at $22.2M in Q2 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.